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Parkinson’s disease (PD) is a neurodegenerative movement disorder of unknown etiology. PD is characterized by the progressive
loss of dopaminergic neurons in the substantia nigra, depletion of dopamine in the striatum, abnormal mitochondrial
and proteasomal functions, and accumulation of α-synuclein that may be closely associated with pathological and clinical
abnormalities. Increasing evidence indicates that both oxidative stress and inﬂammation may play a fundamental role in the
pathogenesis of PD. Oxidative stress is characterized by increase in reactive oxygen species (ROS) and depletion of glutathione.
Lipidmediatorsforoxidativestressinclude4-hydroxynonenal,isoprostanes,isofurans,isoketals,neuroprostanes,andneurofurans.
Neuroinﬂammation is characterized by activated microglial cells that generate proinﬂammatory cytokines, such as TNF-α and IL-
1β. Proinﬂammatory lipid mediators include prostaglandins and platelet activating factor, together with cytokines may play a
prominent role in mediating the progressive neurodegeneration in PD.
1.Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder of
unknownetiology.PDischaracterizedbytheprogressiveloss
of dopaminergic neurons in the substantia nigra pars com-
pacta,whichprojecttothestriatum,theoutputofwhichgov-
erns locomotor behavior [1, 2]. While 90–95% of PD cases
have no known genetic basis, approximately 5–10% arise
from inherited mutations [3] .R o u g h l yh a l fo fe a r l y - o n s e t
PD is caused by loss-of-function mutations in the parkin
gene [4], which encodes an E3 ubiquitin ligase. Although
the molecular mechanism of vulnerability of dopaminergic
neurons in the substantia nigra pars compacta is not
known, it is suggested that monoamine oxidase-mediated
abnormaldopaminemetabolism,hydrogenperoxidegenera-
tion, abnormal mitochondrial and proteasomal dysfunctions
alongwithmicroglialcellactivationmaybecloselyassociated
with neurodegenerative process [5]. Monoamine oxidase
catalyzes the oxidative deamination of dietary amines and
monoamine neurotransmitters, such as serotonin, nore-
pinephrine, dopamine, β-phenylethylamine, and other trace
amines. The rapid degradation of these molecules ensures
the proper functioning of synaptic neurotransmission and is
critically important not only for the regulation of emotional
behaviors, but also for other neural functions. PD is accom-
panied by abnormalities in synaptic neurotransmission in
the basal ganglia. The loss of dopaminergic neurons in the
substantia nigra pars compacta may be related to resting
tremor, rigidity, bradykinesia, postural instability, and gait
disturbanceinPDpatients.Theneuropathologicalhallmarks
of PD include the presence of Lewy bodies mostly composed
of α-synuclein, a presynaptic protein that not only plays an
importantroleinneuropathologyofPD,butisalsoknownto
bind Cu2+, a divalent metal ion, which accelerates the aggre-
gationofα-synucleintoformvarioustoxicaggregatesinvitro
[5, 6]. Neurochemically, PD is characterized by the mito-
chondrial dysfunction, reactive oxygen species (ROS) gener-
ation, nitric oxide (NO) production, excitotoxicity, inﬂam-
mation,accumulationofaberrantormisfoldedproteins,and
ubiquitin-proteasome system dysfunction (Figure 1)[ 1, 2].2 Parkinson’s Disease
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Figure 1: Potential factors and events associated with the pathogenesis of PD.
2. OxidativeStressand
I t sC o ns eq ue nc e sinB rain
Oxidative stress is a cytotoxic condition that occurs in
the tissue when antioxidant mechanisms are overwhelmed
by ROS [7]. Thus, oxidative stress is a threshold phe-
nomenon characterized by a major increase in the amount
of oxidized cellular components. ROS include superox-
ide anions, hydroxyl, alkoxyl, and peroxyl radicals, and
hydrogen peroxide. The major sources of ROS are the
mitochondrial respiratory chain, an uncontrolled arachi-
donic acid (ARA) cascade, and NADPH oxidase (Figure 2)
[8]. These processes utilize molecular oxygen and produce
ROS, which include superoxide anion (O2)a n dH 2O2.
Superoxide is rapidly converted to H2O2 by superoxide
dismutase (SOD), and in turn H2O2 is converted to H2O
by catalase [9]. In the presence of metal ions, such as
Fe2+ and Cu2+,H 2O2 can be further converted to hydroxyl
radical (•OH) through the Fenton reaction. Hydroxyl rad-
icals can attack polyunsaturated fatty acids in membrane
phospholipids forming the peroxyl radical (ROO•)a n d
then propagate the chain reaction of lipid peroxidation
[5].
Low levels of ROS are needed for normal cellular
functions including, but not restricted to, the regulation
of neuronal excitability via redox-sensitive ion channels,
synaptic plasticity, gene transcription, and for the activity of
enzymescontrollingprotein phosphorylation [10].Athigher
concentrations, ROS cause neural membrane damage. The
biological targets of ROS include membrane proteins, unsat-
urated lipids, and DNA [11]. Although neurodegeneration
in neurological disorders is a multifactorial process [5, 12], it
is becoming increasingly evident that the major underlying
factor in the neurological disorders is the increased oxidative
stress substantiated by the ﬁndings that the protein side-
chains are modiﬁed either directly or indirectly by ROS. The
reaction between ROS and proteins or unsaturated lipids
in the plasma membrane also results in the chemical cross-
linking of membrane proteins and lipids and a reduction in
membrane unsaturation. The depletion of unsaturation in
membrane lipids is associated with decreased membrane ﬂu-
idity and decreased activity of membrane-bound enzymes,
ion-channels, and receptors [13].
ROS also attack DNA bases causing damage through
hydroxylation, ring opening, and fragmentation [14]. This
attack generates 8-hydroxy-2 -deoxyguanosine (8-OHdG)
and 2, 6-diamino-4-hydroxy-5-formamidopyrimidine
(FapyGua) [15]. ROS may also attack the sugar phosphate
backbone of DNA [7]. An indication of this DNA damage
comesfromthepresenceoffreebasesinurine.Abstractionof
hydrogenbyROSattheC-4position ofthesugarmoietyalso
produces single-strand breaks in DNA. This is accompanied
by a second sugar oxidation on the complementary strand,
causing a double strand break in DNA. These reactions may
be responsible for the mutagenic eﬀects of ROS in brain
tissue [14].Parkinson’s Disease 3
LOX
Mitochondrial
leakage
GSH
GSSG
2
3 45
Redox regulation
Nucleus
NMDA -R 
PtdCho
Neurodegeneration
NADPH oxidase
resting state
Activated NADPH oxidase
Arginine
Nitrosative
stress  
Oxidative stress 
Symptoms of PD
Isoprostanes and
4-HNE 
1
Activated NADPH oxidase
A
D
M
N
-
R
PAF
PGs Inflammation
P
o
s
i
t
i
v
e
 
l
o
o
p
+
Lyso-PtdCho + ARA
COX-2
Ca2+ cPLA2
O2
ROS
•O2 +NO
OONO−
H2O2
H2O H2O
NADP+
NADPH + H+ NF-κB/IκB
NF-κBt r a n s l o c a t i o n
NF-κB-RE
NF-κβ mediated
gene expression
NF-κβ mediated
enzyme expression
(TNF-α,I L - 1 β)
sPLA2
COX-2
LOX
NOS
SOD
Figure 2: Generation of ROS, activation of NF-κB, redox status, and gene expression in Parkinson’s disease. (1) NADPH oxidase; (2)
superoxide dismutase; (3) catalase; (4) glutathione peroxidase; (5) glutathione reductase; cytosolic phospholipase A2 (cPLA2); secretory
phospholipase A2 (sPLA2); cyclooxygenase-2 (COX), lipoxygenase (LOX); SOD; nitric oxide synthase (NOS); cytokines, TNF-α and IL-1β;
reduced glutathione (GSH); oxidized glutathione (GSSG) and hydrogen peroxide (H2O2). Increase in oxidative stress-mediated expression
of NF-κB induces transcription of sPLA2. COX-2, NOS, and SOD in the nucleus as well as proinﬂammatory cytokines (TNF-α and IL-1β)
that further upregulate activities of cPLA2,s P L A 2, NOS through a positive loop mechanism in cytoplasm and neural membranes.
Activationofnitricoxidesynthase(NOS)generatesnitric
oxide (NO), which reacts with superoxide to form peroxyni-
trite. This molecule oxidatively modiﬁes nucleic acid, lipid,
sugar,andprotein,leadingtonucleardamage,mitochondrial
damage, proteasome inhibition, and endoplasmic reticulum
(ER) stress [16]. NO and peroxynitrite not only decrease
glutathione but also S-nitrosylate many proteins. Excessive
nitrosative stress contributes to the hyperactivation of the
N-methyl-D-aspartate (NMDA)-type glutamate receptor,
mitochondrial dysfunction, and cellular aging. Excessive
generation of free radicals and related molecules (ROS)
and NO species have been reported to trigger pathological
production of misfolded proteins, abnormal mitochon-
drial dynamics (comprised of mitochondrial ﬁssion and
fusion events), and apoptotic pathways in neuronal cells
[17, 18]. Emerging evidence suggests that excessive NO
production can contribute to these pathological processes,
speciﬁcally by S-nitrosylation of speciﬁc target proteins,
such as protein disulﬁde isomerase (PDI), ubiquitin protein
ligase, parkin (forming SNO-parkin), and mitochondrial
fragmentation through β-amyloid-related S-nitrosylation of
dynamin-related protein-1 [18]. Among these proteins, PDI
is responsible for normal protein folding in the endoplasmic
reticulum (ER). S-nitrosylation of PDI compromises its
function and induces misfolding not only in cell cultures
systems, but also in animal models of neurodegenerative
diseases [17, 18]. In addition, NO-mediated eﬀects on
dopaminergic neurons may also include the inhibition of
cytochrome oxidase, ribonucleotide reductase, mitochon-
drial complexes I, II, and IV in the respiratory chain,
superoxide dismutase, glyceraldehyde-3-phosphatedehydro-
genase, activation or initiation of DNA strand breakage,
poly (ADP-ribose) synthase, lipid peroxidation, protein
oxidation, release of iron, and increased generation of toxic
radicals such as hydroxyl radicals and peroxynitrite [19].
Accumulating evidence suggests that excessive ROS/RNS
formation by above-mentioned processes may induce UPS-
impairment and/or misfolding of molecular chaperons, thus
resulting in protein aggregation and neuronal damage [18].
This suggestion supports the possible occurrence of cross-
talk between mitochondria and UPS controlling organelles
(proteasomes). Thus, the production of excessive ROS by
mitochondria may adversely aﬀect UPS activity leading to
neurodegeneration in neurological disorders [12, 20].4 Parkinson’s Disease
Among neural cells, neurons are particularly vulnerable
to oxidative damage not only because of mitochondrial dys-
function [21], but also due to inactivation of glutamine syn-
thetase, which reduces the uptake of glutamate by glial cells
and increases glutamate availability at the synapse producing
excitotoxicity [9]. In addition, neuronal membrane perox-
idative injury may lead to the depletion of unsaturated fatty
acids in neural membranes, which not only causes changes
inmembraneﬂuiditybutalsoaﬀectsactivitiesofmembrane-
bound enzymes, ion channels, and receptors [10].
Glial cell’s response to oxidative stress-mediated neurod-
egenerativeprocessisextremelycomplex.Ononeside,astro-
cytes protect neurons from excitotoxicity through glutamate
uptake system, and on the other side astrocytes contribute
to the extracellular glutamate via reversed glutamate trans-
porter [22]. In addition, astrocytes may undergo astrocytosis
after dopaminergic cell loss and contribute to the inﬂam-
matory response [7]. Microglial cells respond to oxidative
stress-mediated neurodegenerative process by transforming
themselves into activated microglia. They not only change
their shape into “ameboid” morphology, but also release
matrix metalloproteinases, ROS, RNS, prostaglandin E2,a n d
proinﬂammatory cytokines such as TNF-α and IL-β1[ 10].
3.OxidativeStress,NitrosativeStressand
Their Consequences in PD
Involvement of oxidative stress in the pathogenesis of
PD is supported by both postmortem studies and by
studies showing the increased level of oxidative stress in
the substantia nigra pars compacta. A plausible source of
oxidative stress in nigral dopaminergic neurons is the redox
reactions that speciﬁcally involve dopamine and producing
various toxic quinone species (DAQ), such as dopamine-
o-quinone (DQ), aminochrome (AC), and indole-quinone
(IQ). Oxidation products of dopamine have been shown
to alter mitochondrial function, including mitochondrial
swelling and decrease in electron transport chain activity
[23, 24]. Studies on toxic eﬀects of dopamine-derived DAQ
on mitochondria, speciﬁcally on NADH and GSH pools,
indicate that the generation of DAQ in isolated respiring
mitochondria induces the opening of the permeability
transition pore most probably by inducing oxidation of
NADH, while GSH levels are not aﬀected. It is pro-
posed that studies on diverse reactivity for the diﬀerent
DAQ may provide information on the complex molecular
mechanisms underlying oxidative stress and mitochondria
dysfunction in PD. Markers of lipid peroxidation include 4-
hydroxy-trans-2-nonenal (4-HNE), 4-oxo-trans-2-nonenal
(4-ONE), acrolein, isoprostanes, and isofurans are signiﬁ-
cantly increased in PD (Table 1 and Figure 3). These markers
are derived from arachidonic acid (ARA), which is released
from neural membrane glycerophospholipids through the
activation of cytosolic phospholipases A2 (cPLA2). This
enzyme is coupled with NMDA receptors through G protein
independent mechanism [10]. This suggestion is supported
by studies on cPLA2 deﬁcient mice. These mice are resistant
toaspeciﬁcdopaminergicneurotoxicityinducedbythetoxin
Table 1: Levels of mediators, proteins, and factors, which facilitate
and maintain oxidative stress and inﬂammatory responses in PD.
(a)
(A) Lipid mediator Eﬀect Reference
Prostaglandins Increased [10]
Lipid peroxidation Increased [10]
4-Hydroxynonenal Increased [10]
Hydroxycholesterol Increased [32]
8-OHdGua Increased [32]
PINK Increased [33]
Aggregated α-synuclein Increased [34]
NF-κB activity Increased [35]
Oxidative stress Increased [12]
Neuroinﬂammation Increased [12]
Neurodegeneration Increased [12]
(b)
(B) Factors
TNF-α Increased [36]
IL-1β Increased [36]
IL-4 Increased [37]
IL-6 Increased [37]
Epidermal growth factor Increased [36, 37]
Transforming growth factor Increased [36, 37]
Brain-derived neurotrophic factor Decreased [38]
Nerve growth factor Decreased [38]
1-methyl,4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) [25].
In the brain, MPTP is converted to its toxic metabolite,
1-methyl-4-phenylpyridinium ion (MPP+), in the presence
of monoamine oxidase B. MPP+ is actively taken up into
nigrostriatal neurons where it inhibits mitochondrial oxida-
tive phosphorylation leading to neuronal cell death [26].
In MPTP-induced model of Parkinsonism, PLA2 inhibitors
(quinacrine and arachidonyltriﬂuoromethyl ketone) protect
dopaminergic neurons from neurodegeneration [27, 28]. In
addition, the inhibition of COX-2, the enzyme responsi-
ble for the production of proinﬂammatory prostaglandin
(PGE2), not only decreases the lesions caused by MPTP
but also protects dopaminergic neurons in the substantia
nigra. However, the molecular mechanism associated with
COX-2-mediated neurodegeneration in animal model of PD
remains unknown. However, COX-2 inhibition may prevent
the formation of the oxidant species of reactive quinones.
These metabolites are involved in the pathogenesis of PD
[29–31].
Nitric oxide (NO) plays multiple roles in the brain and
spinal cord tissues. In addition to regulating proliferation,
survival and diﬀerentiation of neurons, it is involved in
synaptic activity, neural plasticity, and memory function
[39] .T h ee v i d e n c ef o rt h ei n v o l v e m e n to fN Oi nn e u r o t o x i c
processes associated with PD comes from studies using
experimental models of this disease. NOS inhibitors can
prevent MPTP-mediated dopaminergic neurotoxicity.Parkinson’s Disease 5
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Figure 3: Chemical structures of biomarkers for oxidative stress.
Furthermore, NO not only fosters dopamine depletion, but
NO-mediated neurotoxicity is averted by 7-nitroindazole,
a nNOS inhibitor, in the substantia nigra pars compacta
[19]. Moreover, mutant mice lacking the nNOS gene are
more resistant to MPTP neurotoxicity when compared with
wild-type littermates. Selegiline, an irreversible inhibitor
of monoamine oxidase B, produces beneﬁcial eﬀects in
PD by enhancing dopaminergic function. Selegiline and
its metabolite (desmethylselegiline) also act by reducing
apoptotic cell death by modulating the expression of number
ofgenes,includingsuperoxidedismutase,Bcl-2,Bcl-xl,NOS,
c-Jun, and nicotinamide adenine nucleotide dehydrogenase.
Itislikelythatselegiline-mediated antiapoptotic activitymay
also be involved in the prevention of a progressive reduction
of mitochondrial membrane potential in preapoptotic
neurons [19]. The neuroprotective eﬀects of selegiline may
alsoinvolveneurotrophicfactors(nervegrowthfactor,brain-
derive neurotrophic factor, neurotrophin 3) and ligands
of glial cell line-derived neurotrophic factor [5, 12], which
contribute to neurogenesis in the damaged brains. Excessive
generation of NO may also facilitate the pathological
production of misfolded proteins, abnormal mitochondrial
dynamics (comprised of mitochondrial ﬁssion and fusion
events), and apoptotic pathways in neuronal cells [40]. Thus,
in animal models of PD, S-nitrosylation targets include
parkin, a ubiquitin E3 ligase and neuroprotective molecule,
and protein-disulﬁde isomerase (PDI), a chaperone enzyme
associated with nascent protein folding. S-nitrosylation
of parkin and PDI compromises its ubiquitin E3 ligase
and PDI activities and their protective function suggesting
that nitrosative stress is an important factor in regulating
neuronal survival during the pathogenesis of PD [41, 42].
Signiﬁcant S-nitrosylation of above proteins may contribute
to abnormal mitochondrial fragmentation, resulting in
synaptic damage that is found not only in PD but also
in other neurodegenerative diseases, such as AD and ALS
[40].
4. Inﬂammatory Responses inBrain
Inﬂammation is a protective process that not only isolates
the injured brain tissue from uninjured area but also
destroys aﬀected cells, and repairs the extracellular matrix
[31, 43]. Without a strong inﬂammatory response, brain
would be prone to neurotraumatic and neurodegenerative
diseases. The main mediators of neuroinﬂammation are
microglial cells. They participate in repair and resolution
processes after injury to restore normal tissue homeostasis.
Microglial cells also play an important role as resident
immunocompetent after neural cell injury and disease. As
stated above, during neurodegenerative process, the resting
microglial cells are transformed into activated microglia,
which are characterized by amoeboid morphology [44].
Activated microglial cells not only migrate rapidly to the
site where neurodegenerative process is taking place, but
also engulf dead cells, and clear cellular debris [45, 46].6 Parkinson’s Disease
The chronic activation of microglia in PD may cause
neuronal damage through the release of potentially cytotoxic
molecules such as proinﬂammatory cytokines, ROS, pro-
teinases and complement proteins [5, 11, 44]. Although very
little is known about signaling mechanisms associated with
modulation of microglial activation in PD, it is proposed
that low levels of cytokines and chemokines released by
microglial cells and to lesser extent astrocytes not only
facilitate modulation of neurogenesis through the release of
trophic factors that protect against ROS, and glutamate, but
also promote the removal of dead and damaged neuron [11,
44–46].Incontrast,highlevelsofglialcell-secretedcytokines
and chemokines promote neurodegeneration through the
activation of phospholipases A2 and COX-2 [44]. Emerging
evidence suggests that microglia have a specialized immune
surveillance role and mediate innate immune responses
to neurodegenerative process by secreting a myriad of
factors that include cytokines, chemokines, prostaglandins,
ROS, RNS, and growth factors. Some of these factors have
neuroprotective and trophic activities and aid in brain repair
processes, while others enhance oxidative stress and trigger
neurodegeneration [47].
Twotypesofinﬂammatoryresponses(acuteandchronic)
occur in brain tissue. Acute inﬂammation response devel-
ops rapidly and may be accompanied by pain, whereas
chronic inﬂammation develops slowly and remains below
the threshold of pain perception. As a result, the immune
system continues to attack the brain tissue and chronic
inﬂammation lingers for years, ultimately reaching the
threshold of detection [31]. Inﬂammatory response also
involves recruitment and migration of polymorphonuclear
leukocytes (PMN) and lymphocytes from the blood stream
into brain tissue. This is followed by a process called resolu-
tion, a turning oﬀ mechanism by neural cells to limit tissue
injury.Acuteinﬂammationnormallyresolvesspontaneously,
but the mechanism associated with this process remains
elusive [48].
The chronic activation of microglia may not only cause
neuronal damage through the release of proinﬂammatory
cytokines and chemokines, but also ROS, proteinases and
complement proteins. Very little is known about molecular
mechanisms and internal and external factors that control
and modulate the dynamics of acute and chronic neuroin-
ﬂammation. Collective evidence suggests that inﬂammatory
response involves the interplay not only among microglia,
astrocytes, neurons, PMN, and endothelial cells, but also
among various lipid mediators that originate from enzy-
matic and nonenzymatic degradation of neural membrane
glycerophospholipids sphingolipids and cholesterol [44,
49]. In addition, transcription factors such as peroxisome
proliferator-activated receptor (PPAR) and NF-κB also play
an important role in modulation of inﬂammatory responses.
During inﬂammatory response expression and
activities of a number of enzymes including secretory
phospholipase A2 (sPLA2), cytosolic phospholipase A2
(cPLA2), cyclooxygenase-2 (COX-2), and lipoxygenases
(LOX), that release ARA and convert it to proinﬂammatory
prostaglandin (PGE2)a n dl e u k o t r i e n eB 4,a r em a r k e d l y
increased [44]. Lysophospholipids, the other product of
PLA2 catalyzed reaction is converted to proinﬂammatory
lipid mediator, the platelet-activating factor (PAF).
Generation of prostaglandins and PAF increases the intensity
of inﬂammatory response [12]. During inﬂammatory
response, upregulation of inducible NOS (iNOS) generates
high levels of nitric oxide and peroxynitrite (ONOO−),
which not only nitrates proteins but breaks down into
hydroxyl radicals promoting further intensiﬁcation
of inﬂammatory response. In addition, at the site of
neurodegenerative process, neural and nonneural cells
express and secrete cytokines, chemokine, and complement
proteins, which also play important roles in induction,
propagation, and maintenance of inﬂammatory response
[12, 44].
Cytokines are major eﬀectors of the inﬂammatory
response. Cytokines produce their eﬀects by interacting
with speciﬁc membrane-associated receptors. Cytokines play
an-important role in neural cell response to neurode-
generative processes [50]. Although physiological levels
of cytokines are needed for normal neural cell function
and survival, but increased secretion of cytokines during
neurodegenerative process can be detrimental to neurons
[51]. Tumor necrosis factor-α (TNF-α) and interleukin-1β
(IL-1β) are major cytokines that are upregulated in the
brain tissue during inﬂammatory response (Table 1). In
addition, interleukin-1α (IL-1α), interleukin-3, interleukin-
6 (IL-6), and tumor and growth factors (TGF-α and β)
are also secreted by both microglia and astrocytes during
inﬂammatory response. Accumulating evidence suggests
that secretion and interactions of various cytokines during
inﬂammatory response may result in their synergistic or
antagonistic activities through a complex network that not
only involves their feedback loops, but also modulates
levels of various lipid mediators by regulating activities of
isoforms of PLA2, COX-2, NOS [51, 52]. The consequences
of excessive inﬂammatory response include secretion of high
levels of proinﬂammatory cytokines and chemokines and
production of more free radical causing more oxidative
stress, which can not only damage neurons through the
downregulation of neurotrophins and their receptors but
also by blocking neurogenesis. In addition, the interactions
of cytokines with their receptors result in activation of
cascades of protein kinases, which may lead to the activation
of transcription factor, nuclear factor kappa B (NF-κB).
Activated NF-κB migrates to the nucleus where it mediates
the transcription of many genes implicated in inﬂammatory
and immune responses [44]. These genes include COX-
2, intracellular adhesion molecule-1 (ICAM-1), vascular
adhesion molecule-1 (VCAM-1), E-selectin, TNF-α,I L - 1 β,
IL-6, sPLA2, inducible nitric oxide synthase (iNOS), and
matrix metalloproteinases (MMPs). It is not known whether
inﬂammatory response in neurodegenerative diseases is the
consequence or the cause of neurodegeneration [12].
5. Inﬂammation in PDBrain
Aging, genetic disposition, increase in iron levels, and
environmental factors may trigger the abnormality in pro-
teasomal function leading to the initiation and deposition ofParkinson’s Disease 7
mutated α-synuclein and induction of Lewy body formation
inthebrain(Figure 1).Neuromelanin(NM),anironbinding
complex polymer pigment, interacts with α-synuclein and
contributestoitsaggregation.Neuromelanin(NM)occursin
catecholaminergic neurons of the substantia nigra and locus
coeruleus in human brains and in brains of diﬀerent animal
species [53]. In brain, the conversion of dopamine to NM
through the generation of aminochrome and polymerization
is facilitated by iron, and this process is blocked by iron
chelator, desferrioxamine [53, 54]. The interactions between
iron and NM not only promote NM synthesis but also play
an important role in intraneuronal iron homeostasis [53].
In PD, where nigral iron levels are increased, saturation
of high-aﬃnity iron-binding sites on NM may saturate
the protective capacity of this molecule, leading instead to
an increase in redox-active iron, and subsequent cellular
damage both in vitro and in vivo [53, 55]. The increase
in the release of iron from NM modulates the ubiquitin-
proteasome system in mitochondria, leading to the failure to
clear proteins such as α-synuclein and to the development
of abnormal α-synuclein-immunopositive Lewy bodies that
may facilitate the degeneration of dopaminergic neurons
in PD [55]. During neurodegenerative process, microgliosis
may also play a crucial role. It is proposed that NM acts
as a stimulus and triggers microgliosis in animal and cell
c u l t u r em o d e l so fP D[ 56, 57]. This proposal is supported by
studies on injections of NM in rat brain cerebral cortex and
substantia nigra to monitor microglial cell activation (Iba-
1 and/or GFAP antibody) and neurodegeneration (tyrosine
hydroxylase) [57]. In this study, LPS injections are used as
positive controls and PBS injections are used as negative
controls.TheinjectionsofLPSinduceastronginﬂammatory
response in the cortex as well in the substantia nigra. Similar
results have been obtained in NM injected brains, and
PBS injections induce only moderate or no glial activation.
However, the inﬂammatory response declines during the
time course when LPS and NM were diﬀerent. In the NM
injectedgroupstrongmicrogliaactivationisaccompaniedby
a signiﬁcant dopaminergic cell loss after 1 week of survival
time whereas in LPS-injected, brains inﬂammatory response
declines during thetime course.Theseresultsclearlyindicate
that extracellular NM may be one of the key molecules
leading to microglial activation and neuronal cell death in
the substantia nigra [57]. It is proposed that extraneuronal
melanin may trigger microgliosis, microglial chemotaxis
and microglial activation in PD with subsequent release
of neurotoxic mediators. The addition of human NM to
microglial cell cultures not only produces positive chemotac-
tic eﬀects, but activates the proinﬂammatory transcription
factor nuclear factor-κB( N F - κB) via phosphorylation and
degradation of the inhibitor protein κB( I - κB), and induces
an upregulation of TNF-α,I L - 6a n dN O[ 56]. In addition,
microglial cells secrete a myriad of factors, such as cytokines,
chemokines, prostaglandins, ROS and RNS, and growth
factors [58]. Some of these factors produce neuroprotective
and trophic eﬀects and promote in brain repair processes,
whileothersincreaseoxidativestressandinduceandmediate
apoptotic cascades in neurons. Therefore, pro- and anti-
inﬂammatory responses must be in balance to prevent the
potential detrimental eﬀects of prolonged or unregulated
inﬂammation-induced oxidative stress on vulnerable neu-
ronal populations. Accumulating evidence suggests that in
PD degeneration of dopaminergic neurons in substantia
nigra is accompanied not only by the progressive loss of
NM but also by the induction of microgliosis [59]. Although
NM particles are phagocytized and degraded by microglial
cells within minutes, but extracellular NM particle-mediated
microglial activation results in the generation of superoxide,
nitric oxide, hydrogen peroxide, and other proinﬂammatory
factors including cytokines and chemokines, which support
oxidative stress and inﬂammation in the brain [36, 37, 59].
6. Conclusions
PD is a common neurodegenerative movement disorder,
which aﬀects increasing number of elderly population. The
disorder is caused by a selective degeneration of dopaminer-
gic neurons in the substantia nigra pars compacta. Although
the molecular mechanism associated with neurodegener-
ation in PD is not known, it is becoming increasingly
evident that neurodegeneration in PD is a multifactorial
process that may involve monoamine oxidase-mediated
abnormal dopamine metabolism, increase in iron levels,
hydrogen peroxide generation, abnormal mitochondrial and
proteasomal function along with microgliosis may be closely
associated with the pathogenesis of PD. Microglial cells play
a critical role in forming a self-propelling cycle leading
to sustained chronic neuroinﬂammation and driving the
progressive neurodegeneration in PD. The above-mentioned
processes have been shown to contribute to the oxidative
stress, accumulation of α-synuclein, and neuroinﬂammation
not only in cell culture and animal models of PD, but also in
brains of PD patients.
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